Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02626923

Enrollment

Registered

2015-12-10

Start date

2012-07-31

Completion date

2014-03-31

Last updated

2015-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced Hypotension

Brief summary

Hypotension does not occur with Maraviroc at a dose of 600 mg/day

Detailed description

A qualitative description of orthostatic hypotension in patients receiving once daily Maraviroc at 600 mg with Epzicom measured by a validated questionnaire

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Epzicom Maraviroc once daily dosing

Exclusion criteria

* Maraviroc with any other back bone

Design outcomes

Primary

Measure	Time frame	Description
Hypotension related to once daily Maraviroc dosing	48 Weeks	Blood pressure lowering secondary to Maraviroc 600 mg once daily dosing

Outcome results